251. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome.
- Author
-
Pal L, Berry A, Coraluzzi L, Kustan E, Danton C, Shaw J, and Taylor H
- Subjects
- 25-Hydroxyvitamin D 2 blood, Adult, Body Mass Index, Calcifediol blood, Calcium, Dietary adverse effects, Cholecalciferol administration & dosage, Cholecalciferol adverse effects, Cholecalciferol metabolism, Cohort Studies, Ergocalciferols administration & dosage, Ergocalciferols adverse effects, Ergocalciferols metabolism, Female, Humans, Hyperandrogenism etiology, Hyperandrogenism prevention & control, Hypertension etiology, Hypertension prevention & control, Patient Dropouts, Pilot Projects, Polycystic Ovary Syndrome complications, Polycystic Ovary Syndrome metabolism, Polycystic Ovary Syndrome physiopathology, Testosterone Congeners blood, Vitamin D Deficiency complications, Young Adult, Calcium, Dietary therapeutic use, Cholecalciferol therapeutic use, Dietary Supplements adverse effects, Ergocalciferols therapeutic use, Overweight complications, Polycystic Ovary Syndrome diet therapy, Vitamin D Deficiency diet therapy
- Abstract
Objective: To assess effects of vitamin D and Calcium (Ca) on hormonal and metabolic milieu of polycystic ovary syndrome (PCOS)., Design: Single arm open label trial., Methods: Twelve overweight and vitamin D deficient women with PCOS underwent a 2 hour oral glucose tolerance testing at baseline and following 3-month supplementation with vitamin D (daily dose of 3533 IU, increased to 8533 IU after the first five participants) and 530 mg elemental Ca daily., Main Outcome Measures: Blood pressure (BP), plasma glucose, insulin, total testosterone (T) androstenedione (A), sex hormone binding globulin, lifestyle parameters were assessed at baseline and following 3-month intervention. Insulin resistance (IR) and area under the curve for glucose and insulin were computed; paired analyses were conducted., Results: Improved serum 25OHD (p < 0.001) and reductions in total T (p = 0.036) and A (p = 0.090) levels were noted following 3-month supplementation, compared to baseline. Significant lowering in BP parameters was seen in participants with baseline BP ≥ 120/80 mmHg (n = 8) and in those with baseline serum 25OHD ≤20 ng/ml (n = 9). Parameters of glucose homeostasis and IR remained unchanged (p > 0.05)., Conclusions: Androgen and BP profiles improved followed three month intervention, suggesting therapeutic implications of vitamin D and Ca in overweight and vitamin D deficient women with PCOS.
- Published
- 2012
- Full Text
- View/download PDF